The concept of phenoconversion is central to the argument. A patient’s genotype predicts how their drug-metabolizing enzymes should work, but the clinical phenotype, meaning the enzyme’s actual functional activity, can diverge sharply from that prediction. Drug-drug-gene interactions, inflammation, and organ dysfunction can all shift a person from a normal metabolizer to a poor metabolizer, or the reverse. The cytochrome P-450 enzyme CYP2D6 is especially consequential here because several widely prescribed opioids depend on it. Codeine and tramadol are true prodrugs requiring CYP2D6 activity to be converted into morphine and o-desmethyltramadol respectively. Hydrocodone is partially dependent on the enzyme for conversion to hydromorphone, while oxycodone’s analgesic effect is enhanced by CYP2D6-mediated formation of oxymorphone. When inhibitors such as the antidepressants fluoxetine or bupropion are on board, enzyme-dependent opioids may simply fail to relieve pain. When the inhibitors are withdrawn, the opposite can happen, and opioid potency can surge.

The authors illustrate both directions of this seesaw with composite clinical cases, drawn from observations across multiple patients rather than empirical validation of a population-level effect. In the first case, a 68-year-old farmer with hypertension, diabetes, chronic kidney disease, and depression treated with fluoxetine fell from his tractor and fractured his hip. After surgical fixation, his pain was severe and unrelenting despite escalating doses of hydrocodone and then oxycodone, forcing his transfer to inpatient rehabilitation. On admission, a physician recognized that fluoxetine, a strong CYP2D6 inhibitor, was effectively blocking activation of the enzyme-dependent opioids through phenoconversion. He was switched to morphine, which bypasses CYP2D6, and within 24 hours achieved sustained analgesia on a total of 22.5 milligrams per day, a fraction of the roughly 90 morphine milligram equivalents of oxycodone that had done nothing.

The second case shows the mechanism working in reverse, with near-fatal consequences. A 72-year-old woman on long-term oxycodone for chronic spine-related pain was admitted with pneumonia and agitation, and her inpatient team stopped her bupropion, another strong CYP2D6 inhibitor, suspecting it was worsening her confusion. Her oxycodone dose was left unchanged. Six days later, after transfer to a rehabilitation facility, she suffered sudden respiratory collapse requiring three doses of naloxone. The abrupt discontinuation of bupropion, with its short half-life, had reversed her enzyme inhibition, restoring CYP2D6 activity and accelerating conversion of oxycodone into its more potent metabolite oxymorphone. The authors note that had she been taking fluoxetine, which lingers far longer in the body, the metabolic shift could have occurred after discharge, at home and unmonitored, where fatal apnea would have been a real possibility.

Both cases also carry a message about how such risks surface during transitions of care, the very points where medication changes, discontinuations, and formulary substitutions are routine. Rural older adults frequently move between acute care hospitals, inpatient rehabilitation, and long-term care, each with different levels of geriatric expertise. Without two-way communication, interdisciplinary training, and careful medication reconciliation across settings, unrecognized metabolic shifts can translate into analgesic failure, delirium misdiagnosed as behavioral disturbance, or life-threatening toxicity. The authors suggest that metabolic awareness deserves a place in delirium evaluation itself, since opioid toxicity or abrupt metabolic change can manifest as agitation that is easily misattributed to cognitive impairment or multimorbidity.

Why single out rural communities? The structural context matters enormously. Rural Health Clinics serve as essential access points for medically underserved populations but operate under reimbursement and workflow constraints that limit adoption of anything beyond what fits existing visit types. Pain specialists, geriatricians, behavioral health clinicians, and pharmacists with pharmacogenomics expertise are persistently scarce in rural areas, even though rural residents are more often exposed to medications with pharmacogenomic prescribing guidance. Rurality is correlated with higher rates of opioid prescribing, and geographic isolation plus transportation barriers delay escalation of care, while digital inequities constrain telehealth. Add multimorbidity, polypharmacy, potentially inappropriate medications, and age-related changes in pharmacokinetics and pharmacodynamics, and the conditions for phenoconversion-related harm become more concentrated precisely where the tools to detect it are least available.

The authors are careful about the limits of their claim. Phenoconversion itself is clinically well established, but its contribution to rural pain inequities remains a plausible yet incompletely characterized pathway, and the composite cases cannot establish causality or generalizability. The article frames its proposal explicitly as an implementation-focused roadmap rather than a validated solution. That honesty matters, because the corollary risk is real: precision health interventions introduced unevenly, favoring clinics with integrated electronic health records and embedded specialists, could inadvertently widen the very gaps they aim to close. The authors therefore build low-technology alternatives into their framework, including the Agency for Healthcare Research and Quality’s electronic care plan tools and the PharmDOG drug optimization guidance resource, for clinics lacking genomic modules, reliable internet, or embedded pharmacists.

The roadmap rests on four pillars intended to work in combination. First, clinical decision support infrastructure: routine medication reconciliation, electronic health record-integrated pharmacogenomic results, and alerts that progress from drug-drug interactions to drug-gene interactions and ultimately to drug-drug-gene alerts prioritizing opioids, with interoperability ensured through Health Information Exchange using the FHIR standard so that alerts follow patients across care settings. Second, telehealth-enabled specialty access, including tele-pain and tele-pharmacy consultation pathways, virtual case reviews for complex regimens, and remote pharmacogenomic interpretation. Third, workforce development through case-based learning on phenoconversion, shared decision-making tools, and precision prescribing training spanning primary, acute, rehabilitation, and long-term care. Fourth, system-level support covering reimbursement for pharmacogenomic testing and pharmacist services, broadband expansion, digital literacy support, and state policy levers such as Medicaid coverage of biomarker testing, which Florida has already enacted.

The proposal is grounded in a working example. Archer Family Health Care, a rural health clinic in Archer, Florida, where roughly one in 4.3 adults is over 65, piloted an interdisciplinary precision prescribing model built on the Epic electronic health record’s genomics module. Pharmacists used integrated medication records to generate personalized recommendations in patient-friendly educational formats, and where pharmacogenomic results were available, best-practice alerts provided real-time reminders to clinicians. Early clinician impressions, explicitly framed as quality-improvement experience rather than formally evaluated outcomes, suggested that older adults valued individualized explanations of their medications and that providers grew more confident applying precision principles in a busy primary care setting. The clinic’s reliance on pre-existing digital infrastructure, the authors concede, is an advantage not universally shared.

What emerges is a vision that treats the biology and the structure of rural health care as inseparable. Older adults are not a homogenous group; they differ in genetics, epigenetic changes shaped by life-course exposures, frailty, comorbidity burden, coping strategies, and social context, all of which shape analgesic effectiveness and risk. Precision medicine, combined with shared decision making that brings patient goals, caregiver perspectives, and functional priorities into every medication decision, offers a way to honor that heterogeneity. But as the authors emphasize, translating that promise into equity will require coordinated action across clinical, system, and policy domains, and evidence will be needed to evaluate whether these approaches actually reduce disparities at scale. If they do, the humble rural health clinic may prove to be the unexpected catalyst for a transformation in geriatric pain care, one in which a routine medication change no longer carries the hidden power to rescue or endanger a patient without anyone knowing why.

Subject of Research: Phenoconversion and precision medicine approaches to reduce rural pain management inequities in older adults

Article Title: Phenoconversion and rural pain inequities: a precision-informed roadmap to advance equity for rural older adults

Article References: Hall, A. K., Cicali, E. J., Schentrup, D., & Dubin, A. H. (2026). Phenoconversion and rural pain inequities: a precision-informed roadmap to advance equity for rural older adults. Frontiers in Pain Research, 7, Article 1883083. https://doi.org/10.3389/fpain.2026.1883083

Image Credits: AI Generated

DOI: 10.3389/fpain.2026.1883083

Keywords: phenoconversion, CYP2D6, pharmacogenomics, rural health, geriatric pain, opioids, precision medicine, health equity, polypharmacy, telehealth, clinical decision support, shared decision making

The core problem COSIGT addresses is one of depth. Recent methods such as Locityper have already shown that pangenome references, which store many haplotypes as paths through a graph rather than a single consensus sequence, can dramatically improve targeted genotyping at difficult loci when read data are abundant. Locityper aligns reads to locus-specific haplotypes and selects the best-fitting diploid pair by optimizing alignment accuracy, insert-size concordance, and coverage balance. But that alignment-based likelihood machinery has an Achilles heel: as sequencing coverage falls, the signal-to-noise ratio degrades and genotyping accuracy drops with it. That matters enormously for population-scale studies and biobank cohorts sequenced at variable and often shallow depth, and it matters even more for ancient DNA, where postmortem degradation and microbial contamination routinely push effective coverage below 2X.

COSIGT takes a fundamentally different mathematical route. The pipeline first constructs a local variation graph for the target locus from haplotype-resolved assemblies, rather than querying an entire genome-wide pangenome. This locus-specific design allows parameter tuning, rapid incorporation of new assemblies, and faster genotyping. Reads pre-aligned to the region are extracted, supplemented with unmapped reads rescued by a k-mer filtering tool called kfilt, and then mapped to the local graph. From the graph nodes that reads traverse, the pipeline builds a coverage vector for the sample, in which each element reflects length-normalized, multi-mapping-aware coverage at a node. Every haplotype in the graph is likewise represented as a coverage vector of node traversal counts. COSIGT then enumerates all possible diploid haplotype pairs, sums their vectors to create synthetic genotype profiles, and computes the cosine similarity between each synthetic profile and the observed sample vector. The pair with the highest similarity wins.

The elegance of the approach lies in what cosine similarity measures. Because the metric captures the orientation of a vector rather than its magnitude, it is inherently invariant to overall sequencing depth. A sample sequenced at 1X coverage produces the same relative coverage profile shape as one sequenced at 30X, merely scaled down, and cosine similarity is blind to that scaling. Likelihood-based methods, by contrast, depend on absolute read counts and lose power as counts dwindle. In benchmarks across 326 challenging medically relevant genes and 265 structurally variable regions using short-read data from the 1000 Genomes Project, with pangenome graphs built from assemblies of the Human Pangenome Reference Consortium and the Human Genome Structural Variation Consortium, both COSIGT and Locityper performed well at 5X and 30X coverage, with more than 93 percent high-quality calls. Locityper retained an edge at 30X, reaching 98.2 percent versus 93.9 percent for COSIGT at the medically relevant genes.

At low coverage, the picture reversed dramatically. At 1X, COSIGT delivered 93.4 percent of calls at mid-or-higher quality compared with 84.5 percent for Locityper, and at 2X the gap persisted at 95.8 percent versus 93.4 percent. The advantage became even starker on simulated ancient DNA. Across 48 medically relevant genes enriched for pharmacogenetic and immunogenetic content, including HLAs, CYPs, and mucins, COSIGT maintained roughly 94 percent mid-or-higher quality calls at 1X while Locityper fell to about 46 percent; at 2X the figures were roughly 95 percent versus 60 percent. COSIGT outperformed Locityper at all 48 genes and showed only marginal degradation relative to matched modern DNA at the same coverage. The simulations, generated with a purpose-built simulator called ancestralsim, incorporated realistic ancient DNA damage patterns, short fragment lengths, and contamination levels of 0 or 10 percent, making the result a demanding test.

Robustness to missing references was assessed through leave-all-out benchmarks, in which the true haplotypes of each sample were excluded from the pangenome graph. Even then, COSIGT remained near-optimal, achieving at least 87 percent of the best possible quality at most loci, with 87.6 percent of medically relevant genes and 90.8 percent of structural variant regions falling in the top quintile of achievable quality. An ancestry-mismatched test, in which Peruvian and Colombian samples were genotyped against a graph containing no admixed American assemblies, yielded 87.2 percent high-quality calls at the medically relevant genes, suggesting the method degrades gracefully when the reference panel does not perfectly match the population under study.

The team also demonstrated the tool at genuine population scale. Applying COSIGT to 1,085 whole-genome samples from the Italian Moli-sani cohort, sequenced at roughly 20X coverage, the researchers performed HLA typing across seven classical HLA genes and achieved a mean haplotype-level accuracy of 89.5 percent against types imputed with HLA*IMP:02 from microarray data, comparable to the 90.8 percent achieved by the dedicated HLA genotyping tool T1K. More broadly, the authors report having applied COSIGT to more than 6,000 modern and ancient human genomes, demonstrating population-scalable analysis of complex repeats and multi-copy genes. The pipeline is implemented in Snakemake with containerized deployment, parallelizes across regions and samples, and its per-sample genotyping steps are computationally light, with a median runtime of about 0.02 minutes and median memory use of 52 megabytes for the core genotyping step.

The authors are candid about limitations. Genotyping accuracy ultimately depends on the quality and completeness of the input pangenome: haplotypes absent from the reference panel cannot be called exactly, and novel structural variants will be assigned to the most similar available haplotype. The leave-all-out benchmarks quantify how much accuracy survives this constraint, but they also make clear that expanding pangenome references remains essential. COSIGT currently requires pre-aligned BAM or CRAM files, creating a dependency on reference-based alignment, though future work aims to accept raw FASTQ input directly and to implement haplotype subsampling to keep the method scalable as pangenomes grow. The framework also currently supports diploid genotyping, although the underlying mathematics generalizes to arbitrary ploidy by enumerating k-tuples of haplotypes.

The implications reach well beyond a single software release. Pangenome references are expanding rapidly in size, quality, and taxonomic breadth, and as they do, the bottleneck shifts from reference completeness to scalable genotyping. By making complex-locus genotyping reliable at 1 to 2X coverage, COSIGT opens the door to systematically mining the vast archives of low-coverage sequencing data already sitting in biobanks and legacy datasets, and to bringing archaeological and ancient genomes into population-level biomedical analyses from which their shallow depth previously excluded them. Larger cohorts become affordable at reduced sequencing cost, samples of heterogeneous quality can be combined in a single analysis, and the allelic diversity captured in pangenome references becomes practically accessible across the full spectrum of sequencing depths. The pipeline is compatible with long-read input as well, which could extend its utility to low-coverage long-read datasets too sparse for assembly. For a field that has long treated structurally complex loci as terra incognita in shallow data, the message is that the map, and the compass to read it, may finally have arrived together.

Subject of Research: Pangenome graph-based genotyping of structurally complex genomic loci from low-coverage sequencing data

Article Title: COSIGT: population-scalable genotyping of complex loci from low-coverage sequencing data using pangenome graphs

Article References: Bolognini, D., Guarracino, A., Paleni, C., Dudley, T. S., Iacoviello, L., Raveane, A., Sudmant, P. H., Garrison, E., & Soranzo, N. (2026). COSIGT: population-scalable genotyping of complex loci from low-coverage sequencing data using pangenome graphs. Genome Biology, 27(1), Article 286. https://doi.org/10.1186/s13059-026-04242-4

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04242-4

Keywords: pangenome graphs, genotyping, low-coverage sequencing, ancient DNA, structural variation, copy-number variation, HLA typing, CYP2D6, cosine similarity, population genomics, Genome Biology, bioinformatics